For years, the FDA has allowed progression-free survival to serve as both a primary and surrogate endpoint to support speedy new cancer drug approvals....
A team at Columbia University School of Engineering and Applied Science has developed a technique to enhance chimeric antigen receptor (CAR) T cell therapy...
In the late 1970s, the relationship between the c-Src gene and cancer was discovered. The first oncogene was identified. Credit: Esther Sánchez / CNIO...
Anyone listening to Sarepta’s call Monday after the biotech released trial data for its Duchenne muscular dystrophy gene therapy would have thought the...
British drugmaker GSK plans to acquire an experimental hepatitis B drug from Johnson & Johnson and its developer Arrowhead Pharmaceuticals and then...
New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a promising immunotherapy target for acute myeloid leukemia; decodes genetic...
At 18 Spanish hospitals, when a patient with brain metastasis undergoes surgery, they can donate a tiny part of their brain to the first repository of...
A collaborative study led by researchers from Germans Trias i Pujol Research Institute has revealed the promising possibilities of using an agarose spot...
Aqtual emerged from stealth on Tuesday with $16 million in Series A funds and plans to use its cell-free DNA platform to develop a blood test...
The George Church and Robert Langer labs share a number of commonalities that catalyze success for virtually anyone in their labs willing to seize it....
Sarepta and Roche’s confirmatory study for a Duchenne gene therapy failed to hit its primary endpoint, complicating plans to convert the drug’s label...
Boehringer Ingelheim is going green — with a new brightly-colored logo and revamped corporate palette as part of a broader corporate rebrand. The update...
UC, UC Health mark 10 years as NIH StrokeNet National Coordinating Center, celebrate competitive renewal for next 5 years Credit: University of Cincinnati...
While there are a number of studies demonstrating that dog therapy programs can improve a person’s social and emotional wellbeing, many typically have...
DURHAM, N.C. — For too long, cancer treatment has been a double-edged sword – the very treatments designed to kill cancer cells often wrought havoc...
Executives at gene therapy startup Lexeo Therapeutics will likely make the 25-minute trek from their headquarters to Nasdaq’s trading floor later this...
COLUMBUS, Ohio – A new study from The Ohio State University Wexner Medical Center and College of Medicine, University of Utah and University of Exeter...
Fyodor Urnov, PhD, is a pioneer in the field of genome editing and one of the scientists most invested in expanding the availability and utility of...
After open public discussion and a unanimous board vote, Tri-City Healthcare District (“Tri-City” or “District”) announced yesterday that UC San...
This centuries old martial art was shown to reduce the severity of symptoms in the long-term.
PTC Therapeutics has delayed its plans by nine months to apply for FDA approval of its treatment for phenylketonuria, a rare disease that causes protein...
Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member...
LOS ANGELES — An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS...
Christian Antoni Montai Health has kept most of its business under wraps since emerging from stealth last December. But this week the startup hired its...
Investing in people’s future mental health, based on the key socioeconomic factors underlying it, is the only way to address this rising problem.
Prime Medicine, a biotech company developing a new class of gene editors that promises to make nearly any change to any gene, said the first tests...
In this GEN webinar, Dr. Aleš Štrancar from Sartorius will discuss various chromatographic methods to consistently separate empty, partial, and full...
Among a slew of emerging artificial intelligence biotech companies, BigHat has the potential to transform how next-generation antibodies are designed,...
At the recommended Phase II dose of 5x1011 particle units, six of 12 patients (50%) receiving PRGN-2012 achieved a complete response by no longer needing...
Competitive pressure and a pause in manufacturing due to routine maintenance have pushed US sales of Abecma (idecabtagene vicleucel), Bristol Myers Squibb...